CONCLUSIONS: We used current, nationally representative, population-based, data to demonstrate that the rate of post-prostate biopsy infectious complications continues to increase. Although it is beyond the scope of our study design to assign a reason for this sustained increase, our findings call for an urgent need to identify strategies to effectively combat infectious complications.
INTRODUCTION AND OBJECTIVES:
The risk of prostate needle biopsy (PNBx) infections and sepsis is increasing, with recent estimates of 7% and 3%, respectively. Each post-PNBx infection costs an estimated $5,800 per event. With 165,000 incident prostate cancers annually in the US and greater use of active surveillance, there is greater need for strategies to decrease post-PNBx infections. We performed a meta-analysis with contemporary evidence to evaluate transrectal (TR) vs. transperineal (TP) PNBx infections to determine the importance of biopsy approach.
METHODS: A comprehensive literature search was conducted in July 2018 in Ovid MEDLINE, Ovid EMBASE and Cochrane Library using predefined inclusion/exclusion criteria. Independent reviewers (MG and MA) screened a total of 2898 records and reviewed 49 full texts. Eight studies were included in our final meta-analysis. All doublearm comparative studies, including randomized-controlled trials and cohort studies, reporting the infectious complication rates following prostate biopsy were included. All TP biopsies were performed under general anesthesia. Meta-analysis was performed using the MantelHaenszel Method and Dersimonian-Laird estimator for € I"2. Heterogeneity was analyzed using the Cochrane Q and I2 tests.
RESULTS: TR PNBx was associated with higher odds for infection ( Figure 1) (Figure 2) .
CONCLUSIONS: The meta-analysis demonstrates that TR versus TP PNBx was associated with more than three times higher odds ratio for infectious complications. Our findings may guide the adoption of targeted biopsy and in-office TP approaches, which currently lacks comparative evidence. 
Microbial resistance is an increasing problem in healthcare and antibiotic use should be minimized whenever possible. The guidelines recommend antimicrobial prophylaxis (AMP) in TURP but are mainly based on dated literature. Our study was set up to investigate the current value of AMP in a prospective, multi-centered randomized controlled-trial (RCT).
METHODS: After approval by the ethical committee (B243201733480) a prospective RCT was initiated in 5 hospitals starting from 17 September 2017 to compare AMP vs control in TURP. A power analysis was performed (alpha 0.05 and power 80%) and an inclusion of 556 patients is scheduled in a 1:1 randomization. Exclusion criteria for the study are a pre-operative catheter or pre-operative pyuria > 100 white blood-cells/µL (WBC). Primary endpoint are uncomplicated (< 38.5 C) or complicated (>38.5 C or urosepsis) post-operative urinary tract infection (UTI). Secondary endpoints are post-operative bacteriuria (>105 micro-organisms) at time of hospital discharge and after 4 weeks at the follow-up consultation.
RESULTS: 304 patients are already included since 17 September 2017. Mean pre-op age was 69.8, mean PSA 5 ng/mL and mean prostate volume 55 g. 24/304 (8.2%) Patients have DM-2, 44/304 (14.5%) had a pre-operative cystoscopy and 21/304 (6.5%) urodynamics. Mean operating time 48.9 minutes for a mean resected prostate volume of 26.4 g. Pathology showed active prostatitis in 22/(17.4%) and benign prostate hyperplasia in 233/304 (76.7%) patients. Mean catheter time was 2.2d and mean hospitalization stay 2.4d. 14/304 (4.6%) Patients had a post-operative UTI. Logistic regression could not show a significant difference in favor of AMP (4.3% vs. 4.7% ; p 0.9) in developing UTI in general or complicated UTI (2.2% vs. 3.4% ; p 0.52).
A statistical, non-significant decrease in bacteriuria at time of hospital discharge (5.2% vs. 12.5% ; p 0.57) or at the follow-up consultation (6.3% vs. 15% ; p 0.4) was observed.
CONCLUSIONS: Our preliminary results shows no significant difference in post-operative UTI in favor of AMP in TURP, meaning we can safely continue our study. A slight but statistical not-significant decrease in post-operative bacteriuria at time of hospital discharge and at the follow-up consultation after 4 weeks is observed. Further data collecting and analysis is needed to confirm our preliminary findings. METHODS: Male C57BL/6J (B6) and TRPV1 knockout (TRPV1 KO) mice (5-7 weeks old) were used to induce experimental autoimmune prostatitis (EAP) and compared to respective control cohorts. The prostate lobes, dorsal root ganglia (DRG), and spinal cord were excised at day 20. The prostate lobes were assessed for inflammation, TRPV1 expression, and mast cell activity by blinded observers. The lumbosacral region of the DRG and spinal cord were measured for phosphorylation of ERK1/2 (p-ERK1/2). In addition, B6 mice with EAP received intraurethral administration of a TRPV1 antagonist at day 20 (repeated every two days) and we assessed the development of pain compared to control cohorts at days 20, 25, 30, and 35 . RESULTS: Our data showed that B6 mice with EAP developed markedly enhanced pelvic tactile allodynia at days 7, 14, and 20. Surprisingly, the data revealed that TRPV1 KO mice with EAP do not develop pelvic tactile allodynia between days 7 to 20 and demonstrate a similar tactile response to respective controls. The dorsal and lateral prostate (DLP) lobes excised from B6 mice and TRPV1 K0 with EAP showed increased inflammation. Also, the DLP from B6 mice with EAP contained similar levels of TRPV1 compared to controls. In contrast, B6 mice with EAP showed a significant increase of mast cell activation. Interestingly, the DLP lobes from TRPV1 KO mice with EAP showed a lack of mast cell activation. Next, we observed a significant increase of p-ERK1/2 in the lumbosacral region of the DRG and spinal cord of B6 mice with EAP at day 20; however, p-ERK1/2 expression was unchanged in TRPV1 KO mice with EAP. In a separate experiment, we administered a TRPV1 antagonist peptide intraurethrally to the prostate and blunted the progression of pelvic tactile allodynia in mice with EAP.
CONCLUSIONS: The TRPV1 channel is a key mediator in persistent pelvic pain in EAP and intraurethral delivery of a TRPV1 antagonist peptide to the prostate may be a novel approach to alleviate chronic pelvic pain. (PCa) , controversy exists over both the anatomical extent and survival benefit of PLND during RP. We sought to examine facilitylevel variation in the extent of PLND during RP for clinically localized/ high-risk PCa and to determine if more extensive PLND is associated with a survival benefit.
METHODS: Using data from the National Cancer Data Base, we identified 13,652 men 65 years of age and with a Charlson Comorbidity Index (CCI)[0 receiving care within the United States for biopsy confirmed localized high-risk PCa diagnosed between January 2004 and December 2011. Multilevel, multinomial logistic regression was fitted to predict the odds of receiving different extents of PLND. Inverse propensity weighting (IPTW)-adjusted Cox regression with a Bonferroni correction for multiple endpoint comparisons was fitted to compare risk of overall mortality between the PLND groups. RESULTS: Overall, 11,284 (82.7%), 1,601 (11.7%), and 767 (5.6%) of men undergoing RP underwent concomitant none/limited PLND, standard PLND (sPLND), and extended PLND (ePLND), respectively. ePLND was not associated with a survival benefit relative to sPLND (HR 0.72, p[0.4) nor no/limited PLND (HR 0.77, 95% CI 0.87-2.20; p[0.29) at a median follow-up of 83.3 months. Facility-level predicted probabilities of undergoing ePLND, sPLND, or no/limited PLND ranged from 0.01-52.6%, 3.3-53.3%, and 17.8-96.3%, respectively. CONCLUSIONS: After performing IPTW, we found significant facility-level variation in the extent of PLND during RP despite no apparent survival benefit associated with PLND. Further prospective data is needed to reevaluate what if any role PLND should play in the management of clinically localized PCa treated with RP.
